Firm Secures $69 Million Judgment on Behalf of Gilead Sciences
On November 13, 2026, Patterson Belknap obtained a significant victory for our client, Gilead Sciences, Inc. (“Gilead”), when the U.S. District Court for the Eastern District of New York entered a default judgement awarding Gilead $69,218,326 in damages against a group of distributors of counterfeit Gilead-branded HIV medications.
The lawsuit was brought by Gilead in June 2024 against the defendants, who were alleged to be members of a counterfeiting conspiracy who trafficked counterfeit Gilead-branded medication to patients around the country. This was done by purchasing bottles of the HIV medication from patients, filling them with other medication, sealing the bottles with a fake tamper-evident seal, and reselling them to pharmacies, who then dispensed the counterfeits to unsuspecting patients. At the start of the case, Gilead obtained preliminary injunctions enjoining all the defendants from transacting in Gilead-branded medications. Then, in April 2025, the Court granted Gilead’s motion to enforce a non-party subpoena against a law firm representing one of the defendants in the matter. After her lawyers refused to provide the source of their fee payments, the Court ordered the law firm to produce all of the payment information that Gilead requested. In May 2025, the defendant agreed to a consent judgment with a permanent injunction and monetary payment. Later that month, Gilead obtained a consent judgment for $100 million and a permanent injunction against several other defendants.
In March 2026, Gilead moved for default judgment against more than two dozen other defendants, including retail pharmacies and individuals who trafficked counterfeits. In October, the magistrate judge issued a report and recommendation in which he found that Gilead successfully showed that the defaulted defendants trafficked counterfeit Gilead-branded HIV medications; that Gilead lost more than $23 million in profits as a result of the counterfeit sales; and that the defendants had acted willfully, which meant that Gilead was entitled to trebled damages. Accordingly, the judge recommended that Gilead be awarded damages in the amount of $69,218,326 as well as permanent injunctions against all of the defaulted defendants. The Court adopted that recommendation. The ruling is an important win for combatting the distribution of counterfeit and potentially dangerous medications.
To read the Court’s order, please click here.
To read press coverage from Law360, New York Law Journal, and IP Watchdog please click here, here, and here.